Treatment
-
Clinical Trials: An African American Survivor’s ExperienceMelvin Mann benefited from joining a pivotal clinical trial for chronic myelogenous leukemia, but participation came with logistical challenges.
by Melvin Mann
-
Q&A
The Promise of CRISPRBiochemist Samuel H. Sternberg describes the limitations, realities and potential of gene-editing technology.
by Marci A. Landsmann
-
The Right DoseResearchers want to find out when cancer patients can benefit from receiving lower doses of drugs or radiation, shortening treatment or skipping certain treatments altogether.
by Kate Yandell
-
Exploring Immunotherapy for Triple Negative Breast CancerFollowing the approval of the first immunotherapy for breast cancer by the U.S. Food and Drug Administration in March 2019, experts at the San Antonio Breast Cancer Symposium discussed avenues for further development.
by Marci A. Landsmann
-
Focusing on Proton TherapyProton therapy, an alternative to standard radiation therapy, is safe and effective. But evidence is lacking that it's always a better option than standard radiation, and some insurers balk at the higher price tag.
by Sue Rochman
-
A Switch From Intravenous to Oral Chemo?Compared with intravenous paclitaxel, the oral form of the chemotherapy drug was associated with improved tumor shrinkage in metastatic breast cancer patients.
by Ashley P. Taylor
-
Forward Look
Concerns Raised About MRI Contrast DyeSome patients report unusual side effects after scans.
by Stephen Ornes
-
Possible New Treatments for Patients With Metastatic HER2-Positive Breast CancerStudies presented at the San Antonio Breast Cancer Symposium show additional treatment options.
by Marci A. Landsmann
-
Forward Look
Pediatric Leukemia Treatments Are Not Just for KidsStudy supports using these regimens for teens and young adults.
by Bradley Jones
-
Avoiding Unnecessary Lymph Node BiopsyA study adds to evidence that many patients with ductal carcinoma in situ do not need to have their lymph nodes removed.
by Cheryl Platzman Weinstock
